BAY 1179470

Drug Profile

BAY 1179470

Alternative Names: BAY-1179470; FGFR-moAb; FGFR2-TTC

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacokinetics and Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Aug 2016 Bayer completes a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in Japan, Singapore and South Korea (NCT01881217)
  • 21 Oct 2015 Phase-I development for Solid tumours (Late-stage disease, Second-line therapy or greater) is ongoing in Japan, South Korea and Singapore (NCT01881217)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top